Cargando…
Neoadjuvant treatments in triple-negative breast cancer patients: where we are now and where we are going
Triple-negative breast cancer (TNBC) remains the poorest-prognosis breast cancer (BC) subtype. Gene expression profiling has identified at least six different triple-negative subtypes with different biology and sensitivity to therapies. The heterogeneous nature of TN tumors may justify the difficult...
Autores principales: | Omarini, Claudia, Guaitoli, Giorgia, Pipitone, Stefania, Moscetti, Luca, Cortesi, Laura, Cascinu, Stefano, Piacentini, Federico |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5772398/ https://www.ncbi.nlm.nih.gov/pubmed/29391830 http://dx.doi.org/10.2147/CMAR.S146658 |
Ejemplares similares
-
AI in medicine: Where are we now and where are we going?
por: Shandhi, Md Mobashir Hasan, et al.
Publicado: (2022) -
Intrahepatic Cholangiocarcinoma—Where Are We Now and Where Are We Going to?
por: Wasilewicz, Michał P., et al.
Publicado: (2023) -
Vesicoureteral Reflux: Where Have We Been, Where Are We Now, and Where Are We Going?
por: McLorie, Gordon A.
Publicado: (2008) -
Platelet-Rich Plasma: Where Are We Now and Where Are We Going?
por: Cole, Brian J., et al.
Publicado: (2010) -
Aging with Down Syndrome—Where Are We Now and Where Are We Going?
por: Alldred, Melissa J., et al.
Publicado: (2021)